Close
Achema middle east
swop processing & packaging

Ono Pharma to develop KAI Pharma hyperparathyroid drug

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Lonza Widens Cell and Gene Therapy Suite with New Products

Lonza widens cell and gene therapy suite by way...

No New Drug Submissions by the FDA With Shutdown in Place

The Food and Drug Administration (FDA), which is already...

How to Tell if Your Loved One is Developing an Addiction

Watching a loved one change in ways you do...

The Future of Balding Treatments: What’s New in 2025

Are you balding or thinning out on top? It...

Ono Pharmaceutical has entered into an agreement to develop and commercialize KAI Pharmaceuticals’ lead product candidate KAI-4169 in Japan.

KAI-4169, an intravenous (IV) formulation used in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease-mineral and bone disorder, is in Phase 2 clinical testing.

As per the agreement, Ono receives rights to all indications for injectable formulations of KAI-4169 in Japan and also retains marketing rights in all other regions.KAI will receive $13m as an upfront payment from Ono and will also receive a royalty on sales.

KAI Pharmaceuticals president and CEO Steven James said they are excited about the continued momentum of the KAI-4169 program, and they anticipate completing the Phase 2 trial and reporting data by the end of this year.

Latest stories

Related stories

Lonza Widens Cell and Gene Therapy Suite with New Products

Lonza widens cell and gene therapy suite by way...

No New Drug Submissions by the FDA With Shutdown in Place

The Food and Drug Administration (FDA), which is already...

How to Tell if Your Loved One is Developing an Addiction

Watching a loved one change in ways you do...

The Future of Balding Treatments: What’s New in 2025

Are you balding or thinning out on top? It...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »